Prologis Pharmaceutical announced that its holding subsidiary Ante Yutai recently signed a “Strategic Cooperation Framework Agreement” with Yao Ming Biology and Dorning Biotech to establish long-term strategic partnerships to promote the development of biomacromolecular drug pipelines, etc. The agreement is valid for 5 years, does not involve specific projects or amounts, and has no significant impact on this year's results. If it progresses smoothly in the future, it will have a positive impact. In addition, the controlling shareholders of the company have joined forces to increase their holdings by 6.057,900 shares, accounting for 0.52% of the total share capital. There are no plans to reduce their holdings or lift the ban on restricted shares within the next three months.

Prologis Pharmaceutical announced that its holding subsidiary Ante Yutai recently signed a “Strategic Cooperation Framework Agreement” with Yao Ming Biology and Dorning Biotech to establish long-term strategic partnerships to promote the development of biomacromolecular drug pipelines, etc. The agreement is valid for 5 years, does not involve specific projects or amounts, and has no significant impact on this year's results. If it progresses smoothly in the future, it will have a positive impact. In addition, the controlling shareholders of the company have joined forces to increase their holdings by 6.057,900 shares, accounting for 0.52% of the total share capital. There are no plans to reduce their holdings or lift the ban on restricted shares within the next three months.